FISH involves the application of fluorescent DNA probes specific to genes or genetic regions of interest that highlight abnormalities involving these regions.
FISH for the detection of genetic imbalances or rearrangements conferring prognostic value, often in relation to response to targeted therapy, is a key aspect of the management of an increasing number of tumours of solid tissue.
A small subset of patients with non-small cell lung cancer (NSCLC) carry a rearrangement of the ALK gene. Patients with this rearrangement are likely to respond to the targeted ALK inhibitor crizotininb. ALK rearrangements are detected using an ALK-specific FISH probe.
Additional rare but recurrent rearrangements involving c-MET, which also confer response to crizotinib, can also be screened for on request.
Sample Required See notes section
Turnaround Time 7 days from receipt of tissue section.
FISH for genetic markers in solid tumours is performed on sections from FFPE tissue. If a biopsy has been sent to Imperial for histological investigation it is usually possible to obtain sections for FISH from unused material. If not, please send a paraffin embedded block or FFPE tissue sections.